Sarepta Therapeutics Inc. (SRPT) Receives Outperform Rating from Robert W. Baird
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reaffirmed by investment analysts at Robert W. Baird in a note issued to investors on Monday. They currently have a $102.00 price target on the stock. Robert W. Baird’s price objective would suggest a potential upside of 76.20% from the stock’s previous close.
Several other research firms also recently issued reports on SRPT. Cowen and Company reaffirmed a “market perform” rating on shares of Sarepta Therapeutics in a research note on Monday, August 15th. Janney Montgomery Scott raised Sarepta Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $30.00 to $65.00 in a research note on Monday, September 19th. William Blair reaffirmed an “outperform” rating and set a $88.00 price target on shares of Sarepta Therapeutics in a research note on Sunday, October 2nd. Jefferies Group reaffirmed an “underperform” rating and set a $7.00 price target on shares of Sarepta Therapeutics in a research note on Saturday, June 25th. Finally, JMP Securities reaffirmed an “underperform” rating and set a $10.00 price target on shares of Sarepta Therapeutics in a research note on Sunday, July 24th. One analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $58.44.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 0.40% during mid-day trading on Monday, hitting $57.66. The company had a trading volume of 979,963 shares. The firm has a 50-day moving average of $40.98 and a 200-day moving average of $25.39. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73. The company’s market cap is $2.76 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/sarepta-therapeutics-inc-srpt-receives-outperform-rating-from-robert-w-baird-3.html
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period in the prior year, the firm posted ($0.87) EPS. On average, analysts expect that Sarepta Therapeutics will post ($4.23) EPS for the current year.
In other Sarepta Therapeutics news, SVP David T. Howton sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total value of $420,000.00. Following the completion of the transaction, the senior vice president now owns 28,453 shares in the company, valued at approximately $1,707,180. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Jayant Aphale sold 35,000 shares of the company’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the completion of the transaction, the vice president now owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The disclosure for this sale can be found here. 10.90% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in SRPT. BlackRock Fund Advisors boosted its position in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares in the last quarter. State Street Corp boosted its position in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares in the last quarter. Commonwealth Equity Services Inc bought a new position in Sarepta Therapeutics during the second quarter worth $302,000. National Planning Corp boosted its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares in the last quarter. Hedge funds and other institutional investors own 65.29% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.